Nervous System DiseasesScotomaVision Disorders
Dr. Mark L. Moster, MD
NPI1376511980PAC ID1850339326
- Medicare services, 2023
- 4,831
- Part D claims, 2024
- 125
- Publications
- 41
- Clinical trials
- 7
- MIPS score, 2024
- 87
- Practice address
- 111 S 11th St, Philadelphia, PA 19107
- Practice phone
- Call (215) 955-4038
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Find Dr. Moster's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Mark L. Moster is a neuro-ophthalmology physician in Philadelphia, Pennsylvania
Dr. Moster practices at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania.
Dr. Moster's NPI, 1376511980, was assigned on March 9, 2006. Dr. Moster holds Pennsylvania license MD024148E.
NPI and contact details
- NPI
- 1376511980NPI Registry (opens in a new tab)
- Medicare PAC ID
- 1850339326
- NPI enumeration date
- March 9, 2006
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Practice phone
- (215) 955-4038
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Male
- Estimated age
- 73
- Medical school graduation
- 1979
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Practice Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Mark L. Moster practices at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania
Dr. Moster's primary practice is Thomas Jefferson University Hospital, at 111 S 11th St, Philadelphia, PA 19107 in Philadelphia County. The practice phone is (215) 955-4038.
- Thomas Jefferson University Hospital111 S 11th St, Philadelphia, PA 19107 · Philadelphia CountyPhone(215) 955-4038
Sources: NPPES NPI Registry (CMS); and Dmand AI Practice Data
Dr. Mark L. Moster is affiliated with 3 sites of care and 2 medical groups
Dr. Moster's primary practice is Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. Dr. Moster is also affiliated with Wills Eye Hospital. Dmand AI also links Dr. Moster to 2 more medical groups and 1 group practice or clinic, each named with a free account.
Thomas Jefferson University HospitalPrimary
Sources: NPPES NPI Registry (CMS); Dmand AI Practice Data; Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. Mark L. Moster's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Moster practices, 2 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Thomas Jefferson University Hospital | Available with a free account |
| +2 more sites and 2 medical groups | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
See the EHR and IT leaders at every site where Dr. Moster practices
Dmand AI maps EHR vendors, IT decision makers and buying committees across each health system and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Mark L. Moster is one of 8 neuro-ophthalmology physicians in Pennsylvania
Neuro-ophthalmology is Dr. Moster's primary specialty in the NPI Registry, under taxonomy code 207WX0109X. Dr. Moster is licensed in Pennsylvania.
Specialties and state licenses
- Neuro-ophthalmology, PennsylvaniaPrimary
Neuro-ophthalmology physicians near Dr. Moster
Counts of neuro-ophthalmology physicians with a Dmand AI profile, by place and practice. Each opens the list.
8neuro-ophthalmology physicians in Pennsylvania
8neuro-ophthalmology physicians in Philadelphia
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Mark L. Moster billed Medicare for 4,831 services in 2023
CMS data shows 4,831 Medicare services from Dr. Moster across 12 procedure codes in 2023. Medicare paid $100,244 for them. Every service was in an office.
Medicare services, 20234,831
Paid by Medicare$100,244
Procedure codes12
Dr. Moster's Medicare services by type, 2022 to 2023
- 2022
- 2023
- Drugs given in the office
- 2022: 4,3212023: 3,82911%
- Tests and treatments
- 2022: 6622023: 49425%
- Office and hospital visits
- 2022: 5592023: 45718%
- Surgery
- 2022: 552023: 517%
Dr. Moster's most billed Medicare procedure codes, 2023
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Moster?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Moster and other neuro-ophthalmology physicians in Pennsylvania.
Source: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data
Dr. Mark L. Moster's patients have a median age of 60
Across all payers, Dmand AI patient panel data puts Dr. Moster's median patient age at 60, with 75% women.
Dr. Moster's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 60
Patient panel by sex, all payers
- Women75%
- Men25%
Source: Dmand AI Patient Panel Data
Dr. Mark L. Moster wrote 125 Medicare Part D claims in 2024
In 2024, Dr. Moster wrote 125 Medicare Part D claims for 38 patients. 86% of them were for generic drugs. CMS names the drug for 76 of them, across 2 drugs with 11 or more claims each, at $3,954 in total drug cost. In 2023, CMS named 209 claims across 7 drugs.
Part D claims, 2024125
Drugs named by CMS2
Total drug cost$3,954
Part D patients38
Dr. Moster's Part D claims by kind of drug, 2024
- Generic107 claims86%
- Brand-name18 claims14%
Dr. Moster's most prescribed drugs by claims, 2024
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Part D claims for drugs CMS names, 2023 to 2024
- 2023
- 2024
- Claims for drugs CMS names
- 2023: 2092024: 7664%
Drugs named by CMS: 2 in 2024, 7 in 2023.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. Mark L. Moster scored 87 out of 100 in Medicare's MIPS program for 2024
CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Moster for performance year 2024, reported as part of a group. Dr. Moster accepts Medicare assignment, so Medicare's approved amount is taken as full payment.
- Accepts Medicare assignment
- Yes
Dr. Moster's MIPS scores, performance year 2024
- 87of 100Final score
- 80.8of 100Quality
- 100of 100Promoting Interoperability
- 40of 100Improvement Activities
- 77of 100Cost
Each score is out of 100. The final score weighs the categories CMS scored for this clinician.
Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026
For MedTech and pharma teams
Find neuro-ophthalmology physicians like Dr. Moster by procedure volume and prescribing
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Mark L. Moster has 41 publications on record
Dmand AI links 41 papers to Dr. Moster, published from 2012 to 2024. 2021 was the busiest year, with 3. The most frequent topics are Optic Atrophy, Hereditary, Leber, Genetic Therapy and Magnetic Resonance Imaging. Dr. Moster has published most often in J Neuroophthalmol. Dr. Moster's most frequent co-authors are Robert Charles Sergott, MD, Nancy Jean Newman, MD and Rustum Karanjia, MD, PhD.
Papers41
Years published2012 to 2024
Dr. Moster's papers by year, 2015 to 2024
Topics Dr. Moster writes about most
- Optic Atrophy, Hereditary, Leber
- Genetic Therapy
- Magnetic Resonance Imaging
- Visual Acuity
- DNA, Mitochondrial
- Glaucoma
- Visual Fields
- Dependovirus
Dr. Moster's most frequent co-authors
- Robert Charles Sergott, MD19 shared papers
- Nancy Jean Newman, MD12 shared papers
- Rustum Karanjia, MD, PhD6 shared papers
Recent publications by Dr. Moster
Genes (Basel)
CataractCorneal Dystrophies, HereditaryEye Abnormalities
Am J Ophthalmol
DependovirusGenetic TherapyGenetic Vectors
See who Dr. Moster researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Moster works with, so you can find a warm path to the right neuro-ophthalmology physicians.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Mark L. Moster has worked on 7 clinical trials
Dmand AI links Dr. Moster to 7 clinical trials, 4 of them phase 3 studies. Conditions studied include Optic Atrophy, Hereditary, Leber, Optic Atrophies, Hereditary and Optic Nerve Diseases. GenSight Biologics sponsors the most, 5.
Clinical trials with Dr. Moster by phase
- 1Early phase 1: 1 trial
- NonePhase 1: no trials
- 1Phase 2: 1 trial
- 4Phase 3: 4 trials
- NonePhase 4: no trials
Conditions in Dr. Moster's trials
- Optic Atrophy, Hereditary, Leber
- Optic Atrophies, Hereditary
- Optic Nerve Diseases
- Optic Neuritis
- Optic Neuropathy, Ischemic
Investigators on the most trials with Dr. Moster
- Nancy Jean Newman, MD6 shared trials
- Rudrani Banik, MD2 shared trials
- Rustum Karanjia, MD, PhD2 shared trials
Recent clinical trials with Dr. Moster
Optic Atrophy, Hereditary, LeberOptic Atrophies, HereditaryGS010
Optic Atrophy, Hereditary, LeberOptic Atrophies, HereditaryGS010Sham Intravitreal Injection
Optic Atrophy, Hereditary, LeberOptic Atrophies, Hereditary
A Double-Masked Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Participants With Previous NAION (opens in a new tab)
TerminatedPhase 2
Optic Neuropathy, IschemicOptic Nerve DiseasesRPh201 Cohort ARPh201 Cohort B
Optic Atrophy, Hereditary, LeberOptic Atrophies, HereditaryGS010Sham Intravitreal Injection
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Mark L. Moster received $78,476 in industry payments from 2016 to 2025
CMS Open Payments shows 367 general payments to Dr. Moster from 36 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 52% of the total. Sanofi and Genzyme US Companies paid the most, $51,337.
General payments to Dr. Moster by program year, 2016 to 2025
General payments to Dr. Moster by kind, 2016 to 2025
$78.5Kin total
- Speaker and faculty fees$40,73352%
- Food and beverage$14,84219%
- Consulting fees$10,11013%
- Honoraria$6,5488%
- Other$5,7897%
Companies that paid Dr. Moster the most, 2016 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Sources for Dr. Mark L. Moster's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice Data |
| Primary practice, affiliations and health system | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice DataDmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel Data |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Doctors and Clinicians National Downloadable File (CMS) (opens in a new tab)Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Mark L. Moster
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Mark L. Moster's NPI number?
Dr. Mark L. Moster's NPI number is 1376511980. It was assigned on March 9, 2006, and it is active in the NPI Registry.
What kind of doctor is Dr. Mark L. Moster?
Dr. Mark L. Moster is a neuro-ophthalmology physician in Philadelphia, Pennsylvania. The primary specialty in the NPI Registry is Neuro-ophthalmology Physician (taxonomy code 207WX0109X).
Where does Dr. Mark L. Moster practice?
Dr. Moster practices at 111 S 11th St, Philadelphia, PA 19107. Dr. Moster's primary practice is Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. Dmand AI also links Dr. Moster to 2 medical groups and 1 group practice or clinic.
What is Dr. Mark L. Moster's office phone number?
The practice phone on file for Dr. Moster is (215) 955-4038.
What is Dr. Mark L. Moster's medical license number?
Dr. Moster holds Pennsylvania license MD024148E.
Which hospitals is Dr. Mark L. Moster affiliated with?
Dr. Moster is affiliated with Wills Eye Hospital.
Does Dr. Mark L. Moster accept Medicare?
Yes. CMS data shows Dr. Moster billed Medicare for 4,831 services in 2023, and Dr. Moster accepts Medicare assignment.
What is Dr. Mark L. Moster's MIPS score?
Dr. Moster's MIPS final score for performance year 2024 is 87 out of 100, reported as part of a group.
What services does Dr. Mark L. Moster bill to Medicare?
In 2023, Dr. Moster's most billed Medicare services were injected or infused drug (J0585), eye exam or test (92083) and office visit, established patient (99214).
What drugs does Dr. Mark L. Moster prescribe most?
In 2024 Medicare Part D data, Dr. Moster's most prescribed drugs by claims were Pyridostigmine Bromide and Prednisone.
Show 4 more questionsShow fewer questions
Has Dr. Mark L. Moster received payments from drug or device companies?
CMS Open Payments shows $78,476 in general payments to Dr. Moster from 36 companies from 2016 to 2025. The largest total came from Sanofi and Genzyme US Companies.
How long has Dr. Mark L. Moster been practicing?
Dr. Moster graduated from medical school in 1979, 47 years ago.
Does Dr. Mark L. Moster do research?
Dmand AI links 41 publications to Dr. Moster, published from 2012 to 2024. Dr. Moster has worked on 7 clinical trials.
Who does Dr. Mark L. Moster publish with?
Dr. Moster's most frequent co-authors are Robert Charles Sergott, MD (19 shared papers), Nancy Jean Newman, MD (12 shared papers) and Rustum Karanjia, MD, PhD (6 shared papers).
Selling to neuro-ophthalmology practices?
See neuro-ophthalmology physicians in Pennsylvania by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card